汇宇制药2025年净利预亏2400万元至2900万元

Core Viewpoint - Huiyu Pharmaceutical (688553) is expected to report a net profit attributable to shareholders of between -24 million to -29 million yuan for 2025, representing a year-on-year decline of 107.38% to 108.91% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 indicates a significant loss, with estimates ranging from -24 million to -29 million yuan [1] - This represents a drastic decline of over 100% compared to the previous year's legally disclosed data [1] Group 2: Investment Impact - The company’s investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the stock code 02410.HK [1] - Fluctuations in the stock price of the invested enterprise have led to a fair value change loss of 173 million yuan during the reporting period [1]